Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Jcr Pharmaceuticals Co. Ltd.

Headquarters: Ashiya, Hyogo, Japan
Year Founded: 1975
Status: Public
Industry Sector: HealthTechnology
CEO: Shin Ashida
Number Of Employees: 934
Enterprise Value: $744,557,607
PE Ratio: -282.28
Exchange/Ticker 1: Tokyo:4552
Exchange/Ticker 2: N/A
Latest Market Cap: $417,034,947

BioCentury | Feb 28, 2025
Product Development

Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Dec 20, 2024
Product Development

Long-awaited FDA approval for Mesoblast marks a first in the U.S.

Nearly a decade after Japanese approval, mesenchymal stromal cell therapy approved for pediatric GvHD
BioCentury | Apr 18, 2024
Product Development

Rare disease spotlight: a leukodystrophy with small pipeline behind first approval

At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
BioCentury | Mar 1, 2024
Product Development

Rare disease spotlight: enzyme replacement therapy for the brain

At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Oct 1, 2021
Finance

Sept. 30 Quick Takes: Advent closes €86M second fund

Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more  
BioCentury | Jul 30, 2021
Distillery Therapeutics

In utero base editing may treat Mucopolysaccharidosis type I

DISEASE CATEGORY: Endocrine/Metabolic
INDICATION: Mucopolysaccharidosis In utero base editing could help treat mucopolysaccharidosis type I, a lethal lysosomal storage disease caused by a G to A
BioCentury | May 20, 2021
Deals

Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies

The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | Sep 1, 2018
Politics, Policy & Law

Stepping Through

How regulatory innovation lays the foundation for new business models
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

What the regenerative medicine industry wants from FDA this September
Items per page:
1 - 10 of 73